SCHEMBL269702

SCHEMBL269702

Cc1cc(Cl)ccc1C=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.61
ERN1 O75460 2/20 0.52
ALDH1A1 P00352 5/20 0.48
TSHR P16473 1/20 0.48
CYP3A4 P08684 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44
NPC1 O15118 1/20 0.43
PKM P14618 1/20 0.43
RAB9A P51151 1/20 0.43
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
MPI P34949 1/20 0.42
KMT2A Q03164 1/20 0.42
HPGD P15428 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29957786 0.82 ERN1 (0.57) TDP1ERN1ALDH1A1TSHRCYP3A4
SCHEMBL692253 0.82 ERN1 (0.57) TDP1ERN1ALDH1A1TSHRCYP3A4
SCHEMBL13825831 0.79 ESR2 (0.57) TDP1ALDH1A1TSHRNPC1PKM
SCHEMBL18957581 0.79 MAOA (0.46) TDP1ERN1ALDH1A1TSHRSMN1; SMN2
SCHEMBL10774187 0.79 CYP3A4 (0.43) TDP1ALDH1A1CYP3A4POLBKDM4E
SCHEMBL4357334 0.78 TDP1 (0.70) TDP1ERN1ALDH1A1SMN1; SMN2MEN1
SCHEMBL589945 0.77 CYP3A4 (0.41) TDP1ALDH1A1CYP3A4POLBKDM4E
SCHEMBL9080019 0.77 CYP3A4 (0.41) TDP1ALDH1A1CYP3A4POLBKDM4E
SCHEMBL31615190 0.77 CYP3A4 (0.41) TDP1ALDH1A1CYP3A4POLBKDM4E
SCHEMBL11869494 0.76 ALDH1A1 (0.52) TDP1ERN1ALDH1A1TSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 267 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240033318-A1 PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION OHIO STATE INNOVATION FOUNDATION 2024-02-01 US claimed
US-11576946-B2 Peptidyl inhibitors of calcineurin-NFAT interaction OHIO STATE INNOVATION FOUNDATION (US) 2023-02-14 US claimed
US-20210169966-A1 PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION OHIO STATE INNOVATION FOUNDATION 2021-06-10 US claimed
EP-3749365-A2 PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION Ohio State Innovation Foundation (US) 2020-12-16 EP claimed
CN-111892736-A Polystyrene microsphere for improving sensitivity of latex turbidimetry and preparation method thereof 上海科华生物工程股份有限公司 2020-11-06 CN claimed
WO-2019148194-A2 PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION OHIO STATE INNOVATION FOUNDATION (US) 2019-08-01 WO claimed
EP-1235782-B1 METHOD FOR OXIDATION OF XYLENE DERIVATIVES GEN ELECTRIC (US) 2004-02-18 EP claimed
US-6465685-B1 SUCH AS CHLORO-O-XYLENE, ARE OXIDIZED IN A SOLVENT IN THE PRESENCE OF A METAL COMPOUND CATALYST WITH ADDITION OF PROMOTER AFTER THE REACTION HAS PROCEEDED TO AN INTERMEDIATE STAGE; PRODUCT COMPRISES CHLOROPHTHALIC ACID OR ANHYDRIDE GENERAL ELECTRIC COMPANY 2002-10-15 US claimed
EP-1235781-A1 METHOD FOR OXIDATION OF XYLENE DERIVATIVES GENERAL ELECTRIC COMPANY (US) 2002-09-04 EP claimed
EP-1235782-A1 METHOD FOR OXIDATION OF XYLENE DERIVATIVES GENERAL ELECTRIC COMPANY (US) 2002-09-04 EP claimed
US-6399790-B1 USING METAL CATALYST GENERAL ELECTRIC COMPANY 2002-06-04 US claimed
WO-2001038282-A1 METHOD FOR OXIDATION OF XYLENE DERIVATIVES GENERAL ELECTRIC COMPANY (US) 2001-05-31 WO claimed
WO-2001038281-A1 METHOD FOR OXIDATION OF XYLENE DERIVATIVES GENERAL ELECTRIC COMPANY (US) 2001-05-31 WO claimed
EP-3573972-B1 RORGAMMA MODULATORS AND USES THEREOF GENFIT (FR) 2026-01-14 EP disclosed
US-20250236610-A1 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF BEIGENE, LTD. (KY) 2025-07-24 US disclosed
EP-4562009-A1 NOVEL COMPOUNDS AC Immune SA (CH) 2025-06-04 EP disclosed
US-4153722-A ANTIINFLAMMATORY, A-PHENYL-N-PHENYLNITRONE WILLIAM H. RORER, INC. (US) 1979-05-08 US disclosed
US-4134917-A Method for the denitrosation of organic nitrosamines AMERICAN CYANAMID COMPANY (US) 1979-01-16 US disclosed
US-4126635-A ANTICHOLESTEROL, BLOOD PLATELET AGGREGATION INHIBITION A. H. ROBINS COMPANY, INCORPORATED (US) 1978-11-21 US disclosed
US-4045576-A ANTI-INFLAMMATORY METHODS USING 2-AMINO-3-(5- AND 6-)BENZOYLPHENYLACETIC ACIDS, ESTERS AND METAL SALTS THEREOF AND THE COMPOUNDS A. H. ROBINS COMPANY, INCORPORATED (US) 1977-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210169966-A1 PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION CHP1, NFATC1, PPP3R1 TDP1 3097/4885ERN1 1946/4885ALDH1A1 4853/4885
US-20240033318-A1 PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION CHP1, NFATC1, PPP3R1 TDP1 3049/4885ERN1 1903/4885ALDH1A1 4851/4885
US-11576946-B2 Peptidyl inhibitors of calcineurin-NFAT interaction CHP1, NFATC1, PPP3R1 TDP1 3049/4885ERN1 1903/4885ALDH1A1 4851/4885
US-20250236610-A1 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF HIPK1, HIPK3, HIPK2 TDP1 1712/4885ERN1 721/4885ALDH1A1 3156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.